#BEGIN_DRUGCARD DB00826

# AHFS_Codes:
Not Available

# ATC_Codes:
A01AB10
A07AA03
D01AA02
G01AA02
S01AA10

# Absorption:
Systemic absorption should not be expected following topical administration, and as with other polyene antibiotics, absorption from the gastrointestinal tract is very poor.

# Biotransformation:
Not Available

# Brand_Mixtures:
Not Available

# Brand_Names:
Natacyn
Pimaricin

# CAS_Registry_Number:
7681-93-8

# ChEBI_ID:
Not Available

# Chemical_Formula:
C33H47NO13

# Chemical_IUPAC_Name:
(1R,3S,5R,7R,12R,22R,24S,25R,26S)-22-{[(3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy}-1,3,26-trihydroxy-12-methyl-10-oxo-6,11,28-trioxatricyclo[22.3.1.0^{5,7}]octacosa-8,14,16,18,20-pentaene-25-carboxylic acid

# Chemical_Structure:
Not Available

# Creation_Date:
2005-06-13 07:24:05 -0600

# DPD_Drug_ID_Number:
Not Available

# Description:
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]

# Dosage_Forms:
Suspension / drops	Ophthalmic

# Drug_Category:
Anti-Bacterial Agents
Anti-Infective Agents, Local
Antifungal Agents
Macrolides

# Drug_Interactions:
Not Available

# Drug_Reference:
Not Available

# Drug_Type:
Approved
Small Molecule

# Experimental_Caco2_Permeability:
Not Available

# Experimental_LogP_Hydrophobicity:
1.1

# Experimental_Logs:
-3.21

# Experimental_Water_Solubility:
4100 mg/L (at 21 °C)

# Food_Interactions:
Not Available

# GenBank_ID:
Not Available

# Generic_Name:
Natamycin

# HET_ID:
Not Available

# Half_Life:
Not Available

# InChI_Identifier:
InChI=1S/C33H47NO13/c1-18-10-8-6-4-3-5-7-9-11-21(45-32-30(39)28(34)29(38)19(2)44-32)15-25-27(31(40)41)22(36)17-33(42,47-25)16-20(35)14-24-23(46-24)12-13-26(37)43-18/h3-9,11-13,18-25,27-30,32,35-36,38-39,42H,10,14-17,34H2,1-2H3,(H,40,41)/b4-3+,7-5+,8-6+,11-9+,13-12+/t18-,19-,20+,21+,22+,23-,24-,25+,27-,28+,29-,30+,32?,33-/m1/s1

# InChI_Key:
InChIKey=NCXMLFZGDNKEPB-BQGNJOPGSA-N

# Indication:
For the treatment of fungal blepharitis, conjunctivitis, and keratitis caused by susceptible organisms including <i>Fusarium solani</i> keratitis.

# KEGG_Compound_ID:
C08073

# KEGG_Drug_ID:
D00884

# LIMS_Drug_ID:
826

# Mechanism_Of_Action:
LIke other polyene antibiotics, Natamycin inhibits fungal growth by binding to sterols. Specifically, Natamycin binds to ergosterol in the plasma membrane, preventing ergosterol-dependent fusion of vacuoles, as well as membrane fusion and fission. This differs from the mechanism of most other polyene antibiotics, which tend to work by altering fungal membrane permeability instead.

# Melting_Point:
290 dec °C

# Molecular_Weight_Avg:
665.7252

# Molecular_Weight_Mono:
665.304740595

# Organisms_Affected:
Various Fungus Species

# PDB_Experimental_ID:
Not Available

# PDB_Homology_ID:
Not Available

# PDRhealth_Link:
Not Available

# Pathways:
Not Available

# PharmGKB_ID:
PA164744325

# Pharmacology:
Natamycin is an antifungal drug for topical ophthalmic administration. It is a tetraene polyene antibiotic derived from <i>Streptomyces natalensis</i>. It possesses in vitro activity against a variety of yeast and filamentous fungi, including <i>Candida</i>, <i>Aspergillus</i>, <i>Cephalosporium</i>, <i>Fusarium</i> and <i>Penicillium</i>. Although the activity against fungi is dose-related, natamycin is predominantly fungicidal. Natamycin is not effective in vitro against gram-positive or gram-negative bacteria. Topical administration appears to produce effective concentrations of natamycin within the corneal stroma but not in intraocular fluid.

# Predicted_LogP_Hydrophobicity:
-3.5

# Predicted_LogS:
-3.4

# Predicted_Water_Solubility:
2.78e-01 g/l

# Primary_Accession_No:
DB00826

# Protein_Binding:
Not Available

# PubChem_Compound_ID:
5281099

# PubChem_Substance_ID:
46509171

# RxList_Link:
http://www.rxlist.com/cgi/generic2/natamycin.htm

# Salts:
Not Available

# Secondary_Accession_No:
APRD01136

# Smiles_String_canonical:
Not Available

# Smiles_String_isomeric:
C[C@H]1OC(O[C@@H]2C[C@@H]3O[C@@](O)(C[C@H](O)[C@H]3C(O)=O)C[C@@H](O)C[C@H]3O[C@@H]3\C=C\C(=O)O[C@H](C)C\C=C\C=C\C=C\C=C\2)[C@@H](O)[C@@H](N)[C@@H]1O

# State:
solid

# Structure:
1

# SwissProt_ID:
Not Available

# SwissProt_Name:
Not Available

# Synonyms:
Not Available

# Synthesis_Reference:
Not Available

# Toxicity:
Not Available

# Update_Date:
2013-02-08 16:19:40 -0700

# Wikipedia_Link:
http://en.wikipedia.org/wiki/Natamycin

# pKa_Isoelectric_Point:
Not Available

# Drug_Target_1_Cellular_Location:
Not Available

# Drug_Target_1_Chromosome_Location:
Not Available

# Drug_Target_1_Drug_References:
18165687	te Welscher YM, ten Napel HH, Balague MM, Souza CM, Riezman H, de Kruijff B, Breukink E: Natamycin blocks fungal growth by binding specifically to ergosterol without permeabilizing the membrane. J Biol Chem. 2008 Mar 7;283(10):6393-401. Epub 2007 Dec 29.
20385867	te Welscher YM, Jones L, van Leeuwen MR, Dijksterhuis J, de Kruijff B, Eitzen G, Breukink E: Natamycin inhibits vacuole fusion at the priming phase via a specific interaction with ergosterol. Antimicrob Agents Chemother. 2010 Jun;54(6):2618-25. Epub 2010 Apr 12.

# Drug_Target_1_Essentiality:
Non-Essential

# Drug_Target_1_GenAtlas_ID:
Not Available

# Drug_Target_1_GenBank_ID_Gene:
Not Available

# Drug_Target_1_GenBank_ID_Protein:
Not Available

# Drug_Target_1_GeneCard_ID:
Not Available

# Drug_Target_1_Gene_Name:
Not Available

# Drug_Target_1_Gene_Sequence:
Not Available

# Drug_Target_1_General_Function:
Not Available

# Drug_Target_1_General_References:
Not Available

# Drug_Target_1_HGNC_ID:
Not Available

# Drug_Target_1_HPRD_ID:
Not Available

# Drug_Target_1_ID:
7160

# Drug_Target_1_Locus:
Not Available

# Drug_Target_1_Molecular_Weight:
Not Available

# Drug_Target_1_Name:
Ergosterol, Candida albicans

# Drug_Target_1_Number_of_Residues:
0

# Drug_Target_1_PDB_ID:
Not Available

# Drug_Target_1_Pathway:
Not Available

# Drug_Target_1_Pfam_Domain_Function:
Not Available

# Drug_Target_1_Protein_Sequence:
Not Available

# Drug_Target_1_Reaction:
Not Available

# Drug_Target_1_Signals:
Not Available

# Drug_Target_1_Specific_Function:
Not Available

# Drug_Target_1_SwissProt_ID:
Not Available

# Drug_Target_1_SwissProt_Name:
Not Available

# Drug_Target_1_Synonyms:
Not Available

# Drug_Target_1_Theoretical_pI:
Not Available

# Drug_Target_1_Transmembrane_Regions:
Not Available

#END_DRUGCARD DB00826
